Detail
Článek
Článek online
FT
Medvik - BMČ
  • Je něco špatně v tomto záznamu ?

Analysing the attributes of Comprehensive Cancer Centres and Cancer Centres across Europe to identify key hallmarks

S. Kehrloesser, S. Oberst, W. Westerhuis, A. Wendler, A. Wind, H. Blaauwgeers, JB. Burrion, P. Nagy, G. Saeter, E. Gustafsson, P. De Paoli, J. Lovey, C. Lombardo, T. Philip, D. de Valeriola, M. Docter, F. Boomsma, M. Saghatchian, M. Svoboda, I....

. 2021 ; 15 (5) : 1277-1288. [pub] 20210330

Jazyk angličtina Země Spojené státy americké

Typ dokumentu časopisecké články, práce podpořená grantem

Perzistentní odkaz   https://www.medvik.cz/link/bmc22019710

There is a persistent variation in cancer outcomes among and within European countries suggesting (among other causes) inequalities in access to or delivery of high-quality cancer care. European policy (EU Cancer Mission and Europe's Beating Cancer Plan) is currently moving towards a mission-oriented approach addressing these inequalities. In this study, we used the quantitative and qualitative data of the Organisation of European Cancer Institutes' Accreditation and Designation Programme, relating to 40 large European cancer centres, to describe their current compliance with quality standards, to identify the hallmarks common to all centres and to show the distinctive features of Comprehensive Cancer Centres. All Comprehensive Cancer Centres and Cancer Centres accredited by the Organisation of European Cancer Institutes show good compliance with quality standards related to care, multidisciplinarity and patient centredness. However, Comprehensive Cancer Centres on average showed significantly better scores on indicators related to the volume, quality and integration of translational research, such as high-impact publications, clinical trial activity (especially in phase I and phase IIa trials) and filing more patents as early indicators of innovation. However, irrespective of their size, centres show significant variability regarding effective governance when functioning as entities within larger hospitals.

Citace poskytuje Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc22019710
003      
CZ-PrNML
005      
20220804135927.0
007      
ta
008      
220720s2021 xxu f 000 0|eng||
009      
AR
024    7_
$a 10.1002/1878-0261.12950 $2 doi
035    __
$a (PubMed)33734563
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a xxu
100    1_
$a Kehrloesser, Sebastian $u Cancer Research UK Cambridge Institute, University of Cambridge, Li Ka Shing Centre, UK
245    10
$a Analysing the attributes of Comprehensive Cancer Centres and Cancer Centres across Europe to identify key hallmarks / $c S. Kehrloesser, S. Oberst, W. Westerhuis, A. Wendler, A. Wind, H. Blaauwgeers, JB. Burrion, P. Nagy, G. Saeter, E. Gustafsson, P. De Paoli, J. Lovey, C. Lombardo, T. Philip, D. de Valeriola, M. Docter, F. Boomsma, M. Saghatchian, M. Svoboda, I. Philip, F. Monetti, H. Hummel, G. McVie, R. Otter, W. van Harten
520    9_
$a There is a persistent variation in cancer outcomes among and within European countries suggesting (among other causes) inequalities in access to or delivery of high-quality cancer care. European policy (EU Cancer Mission and Europe's Beating Cancer Plan) is currently moving towards a mission-oriented approach addressing these inequalities. In this study, we used the quantitative and qualitative data of the Organisation of European Cancer Institutes' Accreditation and Designation Programme, relating to 40 large European cancer centres, to describe their current compliance with quality standards, to identify the hallmarks common to all centres and to show the distinctive features of Comprehensive Cancer Centres. All Comprehensive Cancer Centres and Cancer Centres accredited by the Organisation of European Cancer Institutes show good compliance with quality standards related to care, multidisciplinarity and patient centredness. However, Comprehensive Cancer Centres on average showed significantly better scores on indicators related to the volume, quality and integration of translational research, such as high-impact publications, clinical trial activity (especially in phase I and phase IIa trials) and filing more patents as early indicators of innovation. However, irrespective of their size, centres show significant variability regarding effective governance when functioning as entities within larger hospitals.
650    _2
$a akademie a ústavy $x normy $x statistika a číselné údaje $7 D000047
650    _2
$a biomedicínský výzkum $x organizace a řízení $x normy $x statistika a číselné údaje $7 D035843
650    12
$a onkologická péče - zařízení $x organizace a řízení $x statistika a číselné údaje $7 D002173
650    _2
$a kohortové studie $7 D015331
650    _2
$a lidé $7 D006801
650    _2
$a lékařská onkologie $x normy $x statistika a číselné údaje $7 D008495
650    _2
$a nádory $x epidemiologie $x terapie $7 D009369
650    _2
$a týmová péče o pacienty $x organizace a řízení $x normy $x statistika a číselné údaje $7 D010348
650    _2
$a péče orientovaná na pacienta $x organizace a řízení $x normy $x statistika a číselné údaje $7 D018802
650    12
$a kvalita zdravotní péče $7 D011787
650    _2
$a translační biomedicínský výzkum $x metody $x organizace a řízení $x statistika a číselné údaje $7 D057170
651    _2
$a Evropa $x epidemiologie $7 D005060
655    _2
$a časopisecké články $7 D016428
655    _2
$a práce podpořená grantem $7 D013485
700    1_
$a Oberst, Simon $u Organisation of European Cancer Institutes, Brussels, Belgium $u Cancer Research UK Cambridge Centre, University of Cambridge, UK $1 https://orcid.org/0000000211392578
700    1_
$a Westerhuis, Willien $u the Netherlands Comprehensive Cancer Organisation (IKNL), Utrecht, The Netherlands
700    1_
$a Wendler, Astrid $u Cancer Research UK Cambridge Institute, University of Cambridge, Li Ka Shing Centre, UK
700    1_
$a Wind, Anke $u Rijnstate Hospital, Arnhem, The Netherlands
700    1_
$a Blaauwgeers, Harriët $u the Netherlands Comprehensive Cancer Organisation (IKNL), Utrecht, The Netherlands
700    1_
$a Burrion, Jean-Benoit $u Institut Jules Bordet, Université Libre de Bruxelles, Brussels, Belgium
700    1_
$a Nagy, Péter $u National Institute of Oncology, Budapest, Hungary
700    1_
$a Saeter, Gunnar $u Organisation of European Cancer Institutes, Brussels, Belgium $u Division of Cancer Medicine, Oslo University Hospital, Oslo, Norway
700    1_
$a Gustafsson, Eva $u Theme Cancer, Karolinska University Hospital, Stockholm, Sweden
700    1_
$a De Paoli, Paolo $u Alliance Against Cancer, Rome, Italy
700    1_
$a Lovey, József $u Organisation of European Cancer Institutes, Brussels, Belgium $u National Institute of Oncology, Budapest, Hungary
700    1_
$a Lombardo, Claudio $u Organisation of European Cancer Institutes, Brussels, Belgium
700    1_
$a Philip, Thierry $u Organisation of European Cancer Institutes, Brussels, Belgium $u Institut Curie, Paris Cedex 05, France
700    1_
$a de Valeriola, Dominique $u Organisation of European Cancer Institutes, Brussels, Belgium $u Institut Jules Bordet, Université Libre de Bruxelles, Brussels, Belgium
700    1_
$a Docter, Marjet $u Rijnstate Hospital, Arnhem, The Netherlands
700    1_
$a Boomsma, Femke $u Radiotherapeutisch Instituut Friesland, Leeuwarden, The Netherlands
700    1_
$a Saghatchian, Mahasti $u Institut Gustave Roussy, Villejuif, France $u American Hospital of Paris, Neuilly-sur-Seine, France
700    1_
$a Svoboda, Marek $u Masaryk Memorial Cancer Institute, Brno, Czech Republic
700    1_
$a Philip, Irene $u Centre Léon Bérard, Lyon, France
700    1_
$a Monetti, Francesco $u Ospedale Policlinico San Martino, Genova, Italy
700    1_
$a Hummel, Henk $u the Netherlands Comprehensive Cancer Organisation (IKNL), Utrecht, The Netherlands
700    1_
$a McVie, Gordon $u Cancer Intelligence, Bristol, UK
700    1_
$a Otter, Renée
700    1_
$a van Harten, Wim $u Organisation of European Cancer Institutes, Brussels, Belgium $u Rijnstate Hospital, Arnhem, The Netherlands $u The Netherlands Cancer Institute, Amsterdam, The Netherlands $u Department of Health Technology and Services Research, University of Twente, Enschede, The Netherlands
773    0_
$w MED00167281 $t Molecular oncology $x 1878-0261 $g Roč. 15, č. 5 (2021), s. 1277-1288
856    41
$u https://pubmed.ncbi.nlm.nih.gov/33734563 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y p $z 0
990    __
$a 20220720 $b ABA008
991    __
$a 20220804135920 $b ABA008
999    __
$a ok $b bmc $g 1823070 $s 1170953
BAS    __
$a 3
BAS    __
$a PreBMC
BMC    __
$a 2021 $b 15 $c 5 $d 1277-1288 $e 20210330 $i 1878-0261 $m Molecular oncology $n Mol Oncol $x MED00167281
LZP    __
$a Pubmed-20220720

Najít záznam

Citační ukazatele

Možnosti archivace